Microsaic Systems Share Discussion Threads

[stephen2010] 18/1/2018 23:47

If it settles and starts to bounce around that I may but if it continues to drift I will hold out for 2p

[k1ngkonggb] 18/1/2018 23:24

Stephen, so will you be buying at 2.5p then?

[stephen2010] 18/1/2018 22:56

Your a serial ramper moneymoron. And 2.5p is nailed on here. Good luck indeed

[moneymunch] 18/1/2018 14:18

A Trading Statement/Update is expected soon. Gla :-)


28/9/17

Glenn Tracey, CEO commented:

"Following a strategic review, the Board of Microsaic began implementing its revised life sciences strategy early in H1 2017, which is currently focused on the application of its unique miniaturised, point-of-analysis MS instruments for the detection of therapeutic proteins and antibodies ("biologic molecules") in the bioprocessing market.

"The Board sees significant opportunities for its MS instruments to be integrated into the attractive area of bioprocessing, and for diagnostics (disease biomarker detection) in the longer term. MS has a critical role in providing the reliable characterisation needed, and the high deployability and ease of use of Microsaic's technology makes it ideal for these applications compared to traditional instruments.

"Bioprocessing is a crucial stage in the production of biologic drugs, and aims to ensure that they are produced and purified correctly to retain the specific activity given their complex structures, without introducing harmful substances or degrading the biologic product. Point of use MS can be a very powerful tool in this process and recent development initiatives in the application of Microsaic's technology has demonstrated significant improvements in bioprocessing workflows.

"The Board believes that Microsaic's technology is well placed to exploit opportunities in life sciences and is very encouraged with the progress made so far with one of our global partners, hence we are committed to focusing technical and financial resources on opportunities in bioprocessing."

Technological enhancements

The Company has a compelling product development pipeline in support of its bioprocessing applications and in maintaining its leading position in miniaturised MS instruments and technologies. Such enhancements aim to further extend the mass range for biologics detection, and introduce new capabilities, such as on-line desalting, which allows for the purification of biomolecules in real time. In doing so, analysis times can be reduced from weeks to hours, which offers the potential for significant savings in operational costs of bioprocessing.

The Company has also developed a working prototype of a miniaturised "triple quadrupole" instrument, and is welcoming interest from partners for further product development and channels to market for this technology, in life science applications.

Traditional markets

The Company is committed to working with its current OEM partners in small molecule detection. These partnerships provide important insights about customer needs and technology enhancements, as well as the capabilities and robustness of the Company's MS instruments in a real-world environment. Although H1 2017 was a very challenging period for revenues we are pleased to see these increasing again through continued close relationships with our partners. H2 2017 revenues from instruments and consumables are anticipated to be above H1 2017 based on current Q3 performance.

[moneymunch] 18/1/2018 13:51

Lol Stephen, you're pathetic mate....Gl :-)

[stephen2010] 18/1/2018 13:48

Bybe 3's hello 2's. Get out quick as this is heading to mid 2's

[billthebank] 18/1/2018 13:30

This share is being played. A large spread to deter activity partic in a share where there are few shares available. MMs not even offering a price when you go on line to sell either

[k1ngkonggb] 18/1/2018 13:15

Bought a small tranche today but showing as a sell. MM's really want more of this stock!

[moneymunch] 18/1/2018 09:27

Trading statement expected soon.....Gla :-)

[stephen2010] 18/1/2018 09:17

Going sub 3p soon

[moneymunch] 17/1/2018 15:52

"and high accuracy mass spectrometers"

Presumably a reference to Microsaic's latest technology, the 4500 MiD quadrupole minaturized MS as highlighted by the tweet from Microsaic ..gla :-)

Recently, we believe the boundaries for sample limited bioanalysis have been pushed significantly by PharmaFluidics’; micro-Chip chromatography device. The combination of its ultra-high resolution μPAC™ HPLC columns – and high accuracy mass spectrometers – allowed for the identification of more than 3,000 proteins from the equivalent of 50 HeLa cells.

[moneymunch] 17/1/2018 15:44

The future of bioanalysis with microchip chromatography

Posted: 4 January 2018 | Johan Devenyns, Johan Devenyns - PharmaFluidics 

Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further…

Johan Devenyns, CEO PharmaFluidics

THE past few years have seen the introduction of advanced bioanalytical technologies such as next-generation sequencing (NGS) and liquid chromatography/mass spectrometry (LC/ MS). Together, they provide unprecedented power for integrated and systematic investigation of, respectively, cellular genomes, transcriptomes, and their proteomes and metabolomes.

The ‘holy grail’ of proteomics and metabolomics is to decode the proteome and the metabolome at the single cell level. This imposes enormous challenges to sensitivity as there are no amplification methods for proteins and metabolites comparable to those of nucleic acids. Although the current packed bed nano-LC/ MS is generally considered a sensitive approach, it can be associated with limited chromatographic performance, poor column reproducibility and fluidic handling problems – so single cell proteomics has yet to be achieved.

Recently, we believe the boundaries for sample limited bioanalysis have been pushed significantly by PharmaFluidics’ micro-Chip chromatography device. The combination of its ultra-high resolution μPAC™ HPLC columns – and high accuracy mass spectrometers – allowed for the identification of more than 3,000 proteins from the equivalent of 50 HeLa cells.

[moneymunch] 17/1/2018 14:53

Microsaic

@Microsaic

·

Dec 20

When #PharmaFluidics µPAC column meets the #Microsaic 4500 MiD!

The perfect combination for #microfluidic LC-MS applications

(link: microsaic.com/uploads/App%20…

[moneymunch] 17/1/2018 14:52

PharmaFluidics Raises 7.3 Million Euro to Expand Commercialization of Novel Micro-Chip Device for Biomarker, Diagnostics and Drug Development Applications
PharmaFluidics logo (PRNewsfoto/PharmaFluidics)

NEWS PROVIDED BY

PharmaFluidics
Jan 11, 2018, 03:38 ET

GHENT, Belgium, January 11, 2018 /PRNewswire/ --

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 7.3 million euro. The company will focus on intensifying international growth, supported by initial, promising sales.

(Logo: hxxp://mma.prnewswire.com/media/627474/PharmaFluidics_Logo.jpg )

Micro-Chip chromatography company PharmaFluidics closed a financing round of 7.3 million euro from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round.

The VUB spin-off is a disruptive player in the field of micro-Chip Chromatography. Their unique technology - the µPAC™ column series - offers unprecedented robustness and reproducibility as well as state-of-the-art sensitivity and resolution performance. The first clients - academic labs in bio-analysis, bio-pharmaceuticals and diagnostics companies - have confirmed these outstanding characteristics of the µPAC™ technology.

The new funds will be used to further develop the Pillar Array technology platform, to expand the µPAC™ product range, and to scale up production and global sales. "This funding will significantly boost our capacity to support our growth," said PharmaFluidics' Managing Director Johan Devenyns.

Intensified commercialization

The company started shipping µPACᵀ481; columns in September 2017 and has since served proteomics laboratories, medical centers and pharmaceutical companies on three continents: Europe, the USA and Asia. Its pioneering product is very well received and has convinced pioneer users and key opinion leaders in proteomics to use micro-Chip based chromatography.

The unique performance of the µPAC™ columns brings groundbreaking applications within reach. For example, the robustness and reproducibility allow proteomics data from different labs to be pooled, making reliable big data analysis possible. The miniaturization and sensitivity open the door to point-of-care nano-LC-MS, or ultimately single-cell analyses. This market validation as well as the additional potential in new markets have convinced serial life sciences investors RMM SA and Heran BVBA to participate in the current funding round.

[bobmonkeyhouse] 17/1/2018 07:39

Talking BS as usual.

You are a liar and a fraud

[moneymunch] 16/1/2018 17:08

Perfectly poised...Gla ;-)

[stephen2010] 16/1/2018 15:35

Drip drip. 2.5p getting closer
The trend is there ;)

[k1ngkonggb] 16/1/2018 15:29

Cheers Blueshoes

[k1ngkonggb] 16/1/2018 15:29

This is from one monkey to another....you're filtered!!!! :)

[bobmonkeyhouse] 16/1/2018 15:02

pingpong

You need to calm down a bit sonny Jim

It is easy for you just to filter rather getting your skirt wet off your tears.